Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Tracey Winkworth
North London & East Anglia
Want to know more about OMJJARA▼ (momelotinib)?
Get in touch with your local GSK Key Account Manager today to learn more.
Adverse event reporting information can be found at the bottom of this page
Summary of product characteristics & Patient information leaflet for 100 mg (GB)
Summary of product characteristics & Patient information leaflet for 150 mg (GB)
Summary of product characteristics & Patient information leaflet for 200 mg (GB)
Summary of product characteristics & Patient information leaflet (NI)
INDICATION
OMJJARA is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@gsk.com
March 2024 | PM-GB-MML-WCNT-230012 (V1.0)
